Table 2.

Polymorphisms associated with responsiveness among patients with Crohn’s disease, ulcerative colitis, or inflammatory bowel disease treated with adalimumab.

rs	Genotype	Disease	Rf or NRf: n [p (OR/HR; 95% CI)]	Long/Short Term	Response Criteria	Gene	Pathway	Reference
rs10210302	CT or TT	CD	R: 102 [8.11 × 10−4 (OR: 9.44; 2.49–35.83)]	Short	CRP	ATG16L1	Autophagy	[42]
rs10210302	CC	CD	NR: 102 [4.05 × 10−3]	Long	N.D	ATG16L1	Autophagy	[42]
rs10512734	GG	CD	R: 102 [4.62 × 10−3]	Short	IBDQ	PTGER4	T-cell activation	[42]
rs8049439	CT or TT	CD	R: 102 [5.56 × 10−3]	Short	CRP	IL-27	Proinflammatory cytokine	[42]
rs7927894	CC	CD	R: 102 [5.83 × 10−3]	Long	CRP	C11orf30	DNA repair, chromatin organization, and regulation of transcription	[42]
rs1295686	TT	CD	R: 102 [6.07 × 10−3]	Long	IBDQ	IL13	Proinflammatory cytokine	[42]
rs12777960	CC	CD	R: 102 [6.69 × 10−3]	Long	CRP	CCNY	Control cell division cycles and regulate cyclin-dependent kinases	[42]
rs4645983	AA or AG	CD	R: 102 [6.91 × 10−3]	Short	IBDQ	CASP9	Apoptosis	[42]
rs4645983	GG	CD	NR: 102 [7.22 × 10−3]	Short	CRP	CASP9	Apoptosis	[42]
rs3814057	CC	CD	R: 102 [9.64 × 10−3]	Long	CRP	NR12	Adaptive immunity	[42]
rs2241880	GG	CD and UC	NR: 340 [0.026 (aHR: 2.39; 1.11–5.14)]	Long	Inmunogenic, pharmacokinetic, and pharmacodynamic criteria	ATG16L1	Autophagy	[40]

NRf (allele/genotype frequency higher in nonresponsive patients), Rf (allele/genotype frequency higher in responsive patients), CD (Crohn’s disease), UC (ulcerative colitis), CRP (C-reactive protein), IBDQ (Inflammatory Bowel Disease Questionnaire), R (response), NR (non-response), HR (hazards ratio), OR (odds ratio), CI (confidence interval).